Bicara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	171.67	489.71	230.44	4.16
Short-Term Investments	118.49	-	-	-
Cash & Short-Term Investments	290.17	489.71	230.44	4.16
Cash Growth	-44.28%	112.51%	5442.09%	-
Other Current Assets	7.21	12.82	0.63	0.83
Total Current Assets	297.37	502.53	231.07	4.98
Net Property, Plant & Equipment	2.1	0.85	0.82	0.64
Long-Term Investments	117.42	-	-	-
Other Long-Term Assets	7.8	6.62	2.09	1.08
Total Assets	424.69	510	233.98	6.7
Accounts Payable	3.66	4.51	3.19	5.14
Accrued Expenses	16.27	12.88	11.61	18.76
Current Portion of Leases	1.1	0.61	0.29	-
Total Current Liabilities	21.03	17.99	15.09	23.9
Long-Term Leases	0.88	0.13	0.37	-
Other Long-Term Liabilities	-	-	0.02	0.09
Total Long-Term Liabilities	0.88	0.13	0.39	0.09
Total Liabilities	21.91	18.12	15.47	23.98
Common Stock	0.01	0.01	0	0
Additional Paid-in Capital	724.49	712.88	4.25	2.23
Accumulated Other Comprehensive Income	-0.14	-	-	-
Retained Earnings	-321.58	-221.02	-153.02	-101.04
Total Common Shareholders' Equity	402.78	491.88	-148.77	-98.8
Minority Interest	-	-	367.28	81.53
Shareholders' Equity	402.78	491.88	218.51	-17.28
Total Liabilities & Equity	424.69	510	233.98	6.7
Total Debt	1.98	0.74	0.66	0
Net Cash (Debt)	288.19	488.97	229.78	4.16
Net Cash Growth	-41.06%	112.80%	5426.29%	-
Net Cash Per Share	5.29	29.10	396.10	9.69
Book Value	402.78	491.88	-148.77	-98.8
Book Value Per Share	7.39	29.27	-256.45	-230.26
Tangible Book Value	402.78	491.88	-148.77	-98.8
Tangible Book Value Per Share	7.39	29.27	-256.45	-230.26

Updated Nov 10, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q